CD274 and non-small cell lung carcinoma: This evidence suggests that camrelizumab, pembrolizumab based CIT generally be preferred first-line treatments for PD L1-intermediate or negative advanced NSCLC patients; cemiplimab based CIT may also be recommended as a preferred first-line treatment for PD L1-intermediate cohort and Nivolumab+ipilimumab plus chemotherapy for PD-L1 negative patients.